Loading
Cell therapies fail when the tumour stops showing the marker they were built to find. Preparing an alternative product in advance would let doctors switch quickly.
Antigen-negative relapse accounts for a substantial share of CAR-T failures in B-cell malignancies and is emerging in multiple myeloma. Strategies include dual-target and tandem CARs, sequential products, and adaptor or universal CAR platforms whose specificity is set by a separately dosed molecule. A pragmatic programme would monitor antigen density after infusion and have the alternative product manufactured or an adaptor available before relapse.
Shares BCMA, Allogeneic (off-the-shelf) cell therapy, CD20, CD19.
Shares CD20, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares BCMA, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares BCMA, CD20, CD19, CAR-T cell therapy.